Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | LPL | P06858 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015551 | 0.83 | TRPV4 (0.43) | LPLLIPGEGFRESR2AR | |
| SCHEMBL748654 | 0.83 | TRPV4 (0.43) | LPLLIPGEGFRESR2AR | |
| SCHEMBL6216928 | 0.81 | LPL (0.38) | LPLLIPGEGFRESR2PDGFRB | |
| SCHEMBL30376230 | 0.78 | LPL (0.47) | CYP11B2LPLLIPGEGFRCYP11B1 | |
| SCHEMBL751210 | 0.78 | LPL (0.47) | CYP11B2LPLLIPGEGFRCYP11B1 | |
| SCHEMBL1514603 | 0.78 | LPL (0.47) | LPLLIPGEGFRESR2AR | |
| SCHEMBL30375876 | 0.78 | LPL (0.47) | LPLLIPGEGFRESR2AR | |
| SCHEMBL2650626 | 0.78 | LPL (0.41) | CYP11B2LPLLIPGEGFRCYP11B1 | |
| SCHEMBL2656823 | 0.78 | LPL (0.41) | CYP11B2LPLLIPGEGFRCYP11B1 | |
| SCHEMBL6924366 | 0.77 | EGFR (0.39) | CYP11B2LPLLIPGEGFRCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485640-B2 | Imidazopyrazinones as GABA-A receptor anxiolytics | MERCK SHARP & DOHME LIMITED (GB) | 2009-02-03 | — | — | US | disclosed |
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | MERCK SHARP & DOHME LTD. (GB) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014744-A1 | Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic | GABRA3, GABRA2, GABRA1 | CYP11B2 230/4885LPL 4865/4885LIPG 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.